0001632053-19-000007.txt : 20190809 0001632053-19-000007.hdr.sgml : 20190809 20190808174228 ACCESSION NUMBER: 0001632053-19-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190808 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20190809 DATE AS OF CHANGE: 20190808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apotheca Biosciences, Inc. CENTRAL INDEX KEY: 0001632053 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 472055848 STATE OF INCORPORATION: NV FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55467 FILM NUMBER: 191010786 BUSINESS ADDRESS: STREET 1: 10901 ROOSEVELT BLVD., STREET 2: SUITE 1000C CITY: SAINT PETERSBURG STATE: FL ZIP: 33716 BUSINESS PHONE: 727-228-3994 MAIL ADDRESS: STREET 1: 10901 ROOSEVELT BLVD., STREET 2: SUITE 1000C CITY: SAINT PETERSBURG STATE: FL ZIP: 33716 FORMER COMPANY: FORMER CONFORMED NAME: Cannabis Leaf, Inc. DATE OF NAME CHANGE: 20170731 FORMER COMPANY: FORMER CONFORMED NAME: Pacificorp Holdings Ltd. DATE OF NAME CHANGE: 20150128 8-K 1 officer.d.resign.sundar.8819.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 08, 2019

 

 

APOTHECA BIOSCIENCES, INC.

(Exact name of registrant as specified in charter)

 

 

Nevada

000-55467

47-2055848

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

 

10901 Roosevelt Blvd, Suite 1000c

Saint Petersburg, Florida

33716

(Address of principal executive offices)

(Zip Code)

                                                                                                                    

 

(727) 228-3994

Registrant’s telephone number

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

 

 

 

 

 

 

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers. 

 

Effective August 08, 2019, Mr. P.C. Sundareswaran has resigned as the Chairman and CEO of the Company, Apotheca Biosciences.  The decision was based on personal matters not related to any disagreement with the Company. The Company is in the final selection process for its Chief Executive Officer which will replace Mr. P.C. Sundareswaran role.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

APOTHECA BIOSCIENCES IN

 

 

 

 

 

Date:  August 08, 2019

By:

/s/ P.C. Sundar

 

 

 

P.C. Sundar, Chairman & CEO